High-grade gliomas may be able to wire themselves into the healthy brain, receiving and interpreting electrical signals from normal neurons.
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
The first global report on epilepsy has been published by the WHO, which calls for action to make the condition a public health priority.
A promising new study could provide an early warning system to enable people with epilepsy to know when they are at risk of having a seizure.
Researchers have recently found that the brains of children with severe epilepsy can be compensated by rewiring regions of the visual cortex after surgery.
The Epilepsy Society is calling for the UK government to regulate flashing images online. This will help to safeguard individuals with photosensitive epilepsy.
A recently published study has provided evidence that could potentially aid reports into dogs detecting an epileptic seizure odor.
This week we look at a new migraine medicine, a rescheduling of cannabidiol for epilepsy and a successful trial for neuromyelitis optica spectrum disorder.
GW Pharmaceuticals announced the approval of EPIDIOLEX® (cannabidiol) oral solution as the first plant-derived cannabinoid prescription medication.
Hannah Cock provides insight into the current data, controversies and pipelines for the use of cannabis-derived therapeutics in epilepsy.